**Executive takeaway:** Inspira disclosed that it received official approval from Clalit Health Services’ Medical Equipment Committee, which the company characterizes as enabling immediate procurement and operational use of the INSPIRA ART100 across Clalit’s network (approximately 4.9 million members). ["received official approval"](0001213900-26-013436|1) ["network serving approximately 4.9 million"](0001213900-26-013436|1) This matters less as a “regulatory” milestone (ART100 was already FDA-cleared and also received an Israeli Ministry of Health approval) and more as a **hospital-system commercialization unlock**—i.e., being placed on a major integrated provider’s purchasing pathway. ["received 510(k)"](0001213900-25-022325|0) ["Israeli Medical Equipment"](0001213900-25-022325|0) ["initiate procurement processes"](0001213900-26-013436|1) ## 1) What the Clalit approval actually changes (from a commercialization mechanics standpoint) Inspira frames the development as a transition from “regulatory clearance” to “active commercial availability” within Clalit—specifically, approval that allows ART100 to be procured and used operationally across the system. ["transitions the ART100"](0001213900-26-013436|1) ["immediate procurement"](0001213900-26-013436|1) Crucially, the disclosure describes an **internal purchasing/governance approval** (Medical Equipment Committee) rather than a clinical trial result or a new external regulator authorization, and states that it “enables all medical centres within the Clalit network to initiate procurement processes in accordance with the organization’s supply chain protocols.” ["Medical Equipment Committee"](0001213900-26-013436|1) ["initiate procurement processes"](0001213900-26-013436|1) **Why that distinction matters:** for medtech, “cleared” devices can still face long lead times before meaningful sales if they are not (a) vendor-approved, (b) listed in internal catalogs, (c) supported by local clinical champions, and (d) able to clear tendering/budget cycles—especially in large integrated systems with centralized purchasing. Inspira is effectively saying ART100 has crossed a gate that makes procurement procedurally permissible system-wide (subject to each center’s procurement steps). ["enables the INSPIRA™ ART100 system for immediate procurement"](0001213900-26-013436|1) ["initiate procurement processes"](0001213900-26-013436|1) ## 2) Scale and “reference customer” implications Inspira describes Clalit as the “second-largest integrated Health Maintenance Organization (HMO) globally” and emphasizes the size of the network (14 major hospitals and over 1,600 clinics). ["second-largest integrated"](0001213900-26-013436|1) ["14 major hospitals"](0001213900-26-013436|1) ["over 1,600 clinics"](0001213900-26-013436|1) From a go-to-market perspective, this type of disclosure is often aimed at establishing a **Tier-1 proof point** that can be used in other sales cycles (including outside Israel), because large systems’ technical/clinical committees can be perceived as a validation layer by other hospitals and distributors. Inspira explicitly positions the approval as “validation” after a “rigorous technical and clinical review” by a professional committee focused on thoracic and cardiac surgery. ["rigorous technical and clinical review"](0001213900-26-013436|1) ["Thoracic and Cardiac"](0001213900-26-013436|1) ## 3) Product context: ART100 vs. ART500/ART system (why ART100 is the near-term commercial lever) Inspira’s annual report distinguishes between (i) its flagship longer-duration life-support concept (INSPIRA ART / ART500), which it describes as still in development and not tested in humans, and (ii) ART100, which it describes as an FDA-cleared cardiopulmonary bypass (CPB) system for procedures up to six hours. ["has not yet been tested"](0001213900-25-022325|0) ["FDA-cleared"](0001213900-25-022325|0) ["for six hours or less"](0001213900-25-022325|0) That framing suggests ART100 is the company’s **current commercial-stage wedge product** (i.e., something that can be sold now under an established indication), while ART500/ART remains a longer-dated clinical/regulatory development program. ["commercial-stage medical device company"](0001213900-26-013436|1) ["ART system … in the development phase"](0001213900-25-022325|0) The company also disclosed prior milestones that support the “commercial availability” narrative: 510(k) Class II clearance in May 2024, Israeli AMAR approval in July 2024 for ECMO and CPB procedures outside the U.S., and shipment of first devices in December 2024 to Westchester Medical Center as part of an evaluation/collaboration for the INSPIRA ART. ["received 510(k)"](0001213900-25-022325|0) ["AMAR, regulatory approval"](0001213900-25-022325|0) ["first devices were shipped"](0001213900-25-022325|0) ## 4) Revenue potential: what is *known* vs. what remains unproven Inspira’s disclosure is careful to say the approval “enables” procurement and that the company views it as laying a foundation for “potentially long-term, high-quality revenue,” but it does **not** disclose (in the furnished text) a committed purchase quantity, pricing, or a signed multi-year supply agreement. ["foundation for potentially long-term"](0001213900-26-013436|1) So the investable question becomes: does this vendor approval translate into (a) a first purchase order, then (b) repeat orders / multi-site standardization, and eventually (c) pull-through of related disposables/service and/or adjacent products (e.g., HYLA integration) over time. The filing supports the “procurement pathway open” claim, but does not yet provide the quantitative commercial proof points that would let an analyst model near-term revenue with confidence. ["initiate procurement processes"](0001213900-26-013436|1) ## 5) Capital and dilution context (why financing cadence matters right now) The company’s FY2024 financial statements show it ended December 31, 2024 with cash and cash equivalents of $5.111 million (USD, in thousands). ["Cash and cash equivalents"](0001013762-25-004105|0) In Feb. 2026, Inspira disclosed a registered direct offering with a single institutional investor: 4,000,000 ordinary shares at $0.70 and pre-funded warrants for up to 2,785,715 shares (with a nominal $0.0001 exercise price), plus terms that restrict additional issuance/registration statements for 60 days post-close (subject to exceptions). ["4,000,000 … at … $0.70"](0001213900-26-013042|0) ["pre-funded warrants"](0001213900-26-013042|0) ["exercise price of $0.0001"](0001213900-26-013042|0) ["period of 60 days"](0001213900-26-013042|0) The company also disclosed it amended December 2023 warrants held by that investor to reduce the exercise price to $0.70 and extend the expiration to February 5, 2031 (from June 27, 2027). ["reduce the exercise price"](0001213900-26-013042|0) ["extend the expiration"](0001213900-26-013042|0) **Why this matters for the Clalit commercialization read-through:** vendor approvals are valuable, but converting them into installations can require working capital (inventory build, field support, training, service infrastructure). The Feb. 2026 financing disclosure indicates the company is still actively raising capital and adjusting warrant overhang, which can both fund commercialization and increase dilution/volatility. ["gross proceeds … $4.75 million"](0001213900-26-013042|8) ["warrants … exercise price … $0.70"](0001213900-26-013042|8) ## 6) Market behavior context (short-term trading vs. fundamentals) As of the latest available price-change snapshot in the financial database, IINN shows a -26.35% 1-month move and -39.17% 6-month move (percent change). ["1 Month % Change | -26.35391"](01d0p7) ["6 Month % Change | -39.16964"](01d0p7) This kind of drawdown can amplify the importance of near-term commercial evidence (e.g., first Clalit purchase orders, number of deployed systems, utilization metrics), because the equity market often demands “proof of conversion” after major procurement-pathway announcements. (No filing currently in the retrieved set provides those quantitative conversion metrics.) ["initiate procurement processes"](0001213900-26-013436|1) ## 7) What I would watch next in filings/disclosures (concrete, falsifiable milestones) 1) **First Clalit purchase order / number of ART100 systems procured** and the timing of deployment across sites (this is the key missing quantitative bridge from approval → revenue). ["immediate procurement"](0001213900-26-013436|1) 2) **Commercial terms disclosure** (pricing, service contracts, disposables pull-through, tender framework), if material. ["foundation for potentially long-term"](0001213900-26-013436|1) 3) **Updates on U.S. commercialization** that use this as a reference case (the company explicitly links the validation to accelerating commercialization in the U.S. and other markets). ["accelerate our commercialization efforts"](0001213900-26-013436|1) 4) **Liquidity runway updates** and additional financings (given the company’s historical net loss profile and ongoing financing activity). ["Total comprehensive and net loss"](0001013762-25-004105|0) ["registered direct offering"](0001213900-26-013042|0) If you want, I can also pull and summarize any subsequent 6-Ks after Feb 9, 2026 that mention Clalit, ART100 deployments, purchase orders, or revenue recognition specifics (to see whether the company provides the quantitative follow-through the market will likely demand). ["For the Month of February 2026"](0001213900-26-013436|0)

**Executive takeaway:** Inspira disclosed that it received official approval from Clalit Health Services’ Medical Equipment Committee, which the company characterizes as enabling immediate procurement and operational use of the INSPIRA ART100 across Clalit’s network (approximately 4.9 million members). ["received official approval"](0001213900-26-013436|1) ["network serving approximately 4.9 million"](0001213900-26-013436|1) This matters less as a “regulatory” milestone (ART100 was already FDA-cleared and also received an Israeli Ministry of Health approval) and more as a **hospital-system commercialization unlock**—i.e., being placed on a major integrated provider’s purchasing pathway. ["received 510(k)"](0001213900-25-022325|0) ["Israeli Medical Equipment"](0001213900-25-022325|0) ["initiate procurement processes"](0001213900-26-013436|1) ## 1) What the Clalit approval actually changes (from a commercialization mechanics standpoint) Inspira frames the development as a transition from “regulatory clearance” to “active commercial availability” within Clalit—specifically, approval that allows ART100 to be procured and used operationally across the system. ["transitions the ART100"](0001213900-26-013436|1) ["immediate procurement"](0001213900-26-013436|1) Crucially, the disclosure describes an **internal purchasing/governance approval** (Medical Equipment Committee) rather than a clinical trial result or a new external regulator authorization, and states that it “enables all medical centres within the Clalit network to initiate procurement processes in accordance with the organization’s supply chain protocols.” ["Medical Equipment Committee"](0001213900-26-013436|1) ["initiate procurement processes"](0001213900-26-013436|1) **Why that distinction matters:** for medtech, “cleared” devices can still face long lead times before meaningful sales if they are not (a) vendor-approved, (b) listed in internal catalogs, (c) supported by local clinical champions, and (d) able to clear tendering/budget cycles—especially in large integrated systems with centralized purchasing. Inspira is effectively saying ART100 has crossed a gate that makes procurement procedurally permissible system-wide (subject to each center’s procurement steps). ["enables the INSPIRA™ ART100 system for immediate procurement"](0001213900-26-013436|1) ["initiate procurement processes"](0001213900-26-013436|1) ## 2) Scale and “reference customer” implications Inspira describes Clalit as the “second-largest integrated Health Maintenance Organization (HMO) globally” and emphasizes the size of the network (14 major hospitals and over 1,600 clinics). ["second-largest integrated"](0001213900-26-013436|1) ["14 major hospitals"](0001213900-26-013436|1) ["over 1,600 clinics"](0001213900-26-013436|1) From a go-to-market perspective, this type of disclosure is often aimed at establishing a **Tier-1 proof point** that can be used in other sales cycles (including outside Israel), because large systems’ technical/clinical committees can be perceived as a validation layer by other hospitals and distributors. Inspira explicitly positions the approval as “validation” after a “rigorous technical and clinical review” by a professional committee focused on thoracic and cardiac surgery. ["rigorous technical and clinical review"](0001213900-26-013436|1) ["Thoracic and Cardiac"](0001213900-26-013436|1) ## 3) Product context: ART100 vs. ART500/ART system (why ART100 is the near-term commercial lever) Inspira’s annual report distinguishes between (i) its flagship longer-duration life-support concept (INSPIRA ART / ART500), which it describes as still in development and not tested in humans, and (ii) ART100, which it describes as an FDA-cleared cardiopulmonary bypass (CPB) system for procedures up to six hours. ["has not yet been tested"](0001213900-25-022325|0) ["FDA-cleared"](0001213900-25-022325|0) ["for six hours or less"](0001213900-25-022325|0) That framing suggests ART100 is the company’s **current commercial-stage wedge product** (i.e., something that can be sold now under an established indication), while ART500/ART remains a longer-dated clinical/regulatory development program. ["commercial-stage medical device company"](0001213900-26-013436|1) ["ART system … in the development phase"](0001213900-25-022325|0) The company also disclosed prior milestones that support the “commercial availability” narrative: 510(k) Class II clearance in May 2024, Israeli AMAR approval in July 2024 for ECMO and CPB procedures outside the U.S., and shipment of first devices in December 2024 to Westchester Medical Center as part of an evaluation/collaboration for the INSPIRA ART. ["received 510(k)"](0001213900-25-022325|0) ["AMAR, regulatory approval"](0001213900-25-022325|0) ["first devices were shipped"](0001213900-25-022325|0) ## 4) Revenue potential: what is *known* vs. what remains unproven Inspira’s disclosure is careful to say the approval “enables” procurement and that the company views it as laying a foundation for “potentially long-term, high-quality revenue,” but it does **not** disclose (in the furnished text) a committed purchase quantity, pricing, or a signed multi-year supply agreement. ["foundation for potentially long-term"](0001213900-26-013436|1) So the investable question becomes: does this vendor approval translate into (a) a first purchase order, then (b) repeat orders / multi-site standardization, and eventually (c) pull-through of related disposables/service and/or adjacent products (e.g., HYLA integration) over time. The filing supports the “procurement pathway open” claim, but does not yet provide the quantitative commercial proof points that would let an analyst model near-term revenue with confidence. ["initiate procurement processes"](0001213900-26-013436|1) ## 5) Capital and dilution context (why financing cadence matters right now) The company’s FY2024 financial statements show it ended December 31, 2024 with cash and cash equivalents of $5.111 million (USD, in thousands). ["Cash and cash equivalents"](0001013762-25-004105|0) In Feb. 2026, Inspira disclosed a registered direct offering with a single institutional investor: 4,000,000 ordinary shares at $0.70 and pre-funded warrants for up to 2,785,715 shares (with a nominal $0.0001 exercise price), plus terms that restrict additional issuance/registration statements for 60 days post-close (subject to exceptions). ["4,000,000 … at … $0.70"](0001213900-26-013042|0) ["pre-funded warrants"](0001213900-26-013042|0) ["exercise price of $0.0001"](0001213900-26-013042|0) ["period of 60 days"](0001213900-26-013042|0) The company also disclosed it amended December 2023 warrants held by that investor to reduce the exercise price to $0.70 and extend the expiration to February 5, 2031 (from June 27, 2027). ["reduce the exercise price"](0001213900-26-013042|0) ["extend the expiration"](0001213900-26-013042|0) **Why this matters for the Clalit commercialization read-through:** vendor approvals are valuable, but converting them into installations can require working capital (inventory build, field support, training, service infrastructure). The Feb. 2026 financing disclosure indicates the company is still actively raising capital and adjusting warrant overhang, which can both fund commercialization and increase dilution/volatility. ["gross proceeds … $4.75 million"](0001213900-26-013042|8) ["warrants … exercise price … $0.70"](0001213900-26-013042|8) ## 6) Market behavior context (short-term trading vs. fundamentals) As of the latest available price-change snapshot in the financial database, IINN shows a -26.35% 1-month move and -39.17% 6-month move (percent change). ["1 Month % Change | -26.35391"](01d0p7) ["6 Month % Change | -39.16964"](01d0p7) This kind of drawdown can amplify the importance of near-term commercial evidence (e.g., first Clalit purchase orders, number of deployed systems, utilization metrics), because the equity market often demands “proof of conversion” after major procurement-pathway announcements. (No filing currently in the retrieved set provides those quantitative conversion metrics.) ["initiate procurement processes"](0001213900-26-013436|1) ## 7) What I would watch next in filings/disclosures (concrete, falsifiable milestones) 1) **First Clalit purchase order / number of ART100 systems procured** and the timing of deployment across sites (this is the key missing quantitative bridge from approval → revenue). ["immediate procurement"](0001213900-26-013436|1) 2) **Commercial terms disclosure** (pricing, service contracts, disposables pull-through, tender framework), if material. ["foundation for potentially long-term"](0001213900-26-013436|1) 3) **Updates on U.S. commercialization** that use this as a reference case (the company explicitly links the validation to accelerating commercialization in the U.S. and other markets). ["accelerate our commercialization efforts"](0001213900-26-013436|1) 4) **Liquidity runway updates** and additional financings (given the company’s historical net loss profile and ongoing financing activity). ["Total comprehensive and net loss"](0001013762-25-004105|0) ["registered direct offering"](0001213900-26-013042|0) If you want, I can also pull and summarize any subsequent 6-Ks after Feb 9, 2026 that mention Clalit, ART100 deployments, purchase orders, or revenue recognition specifics (to see whether the company provides the quantitative follow-through the market will likely demand). ["For the Month of February 2026"](0001213900-26-013436|0)